Pulmonary Drugs Market - Forecast(2024 - 2030)

Pulmonary Drugs Market Overview

Pulmonary Drugs Market size is estimated to reach $68.7 billion by 2027, growing at a CAGR of 3.5% during the forecast period 2022-2027. Pulmonary drugs can treat an extensive series of conditions, which are involved within the scope of pulmonary ailments like pneumonia, allergic rhinitis, pulmonary hypertension, and others. Pulmonary delivery of drugs utilizing dry powder inhalers (DPI) is a rising approach to treating tuberculosis (TB). Compared to the traditional pulmonary delivery for asthma and chronic obstructive pulmonary disease (COPD), TB needs high dose delivery to the lung. Antihistamines are medications that treat allergic rhinitis, common cold, influenza, and additional allergies. Usually, people consume antihistamines as an economical, generic, medication that can be purchased without a prescription and offers alleviation from nasal congestion, sneezing, or hives brought about by pollen, dust mites, or animal allergy with not many side effects. In pulmonary ailments, monoclonal antibodies have been tested principally in asthma with important outcomes. The anti-IgE and the anti-interleukin-5 (IL-5) antibodies are presently a portion of the typical treatment of serious asthma. Metered Dose Inhalers (MDIs) are one of the two principal kinds of inhalers for the delivery of respiratory medications, for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The other is Dry Powder Inhalers. MDIs are also termed pMDIs (pressurised metered dose inhalers).

The extensive application of pulmonary drugs in the treatment of all kinds of pulmonary ailments is set to drive the Pulmonary Drugs Market. The enormous environmental pollution in metropolitan cities and industrial lands resulting in respiratory ailments involving the application of antihistamines is set to propel the growth of the Pulmonary Drugs Market during the forecast period 2022-2027. This represents the Pulmonary Drugs Industry Outlook.

Report Coverage

The report: “Pulmonary Drugs Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Pulmonary Drugs Market.

By Drug Class: Beta-2 Agonists, Anti-Cholinergic Agents, Oral And Inhaled Corticosteroids, Anti-Leukotrienes, Antihistamines, Monoclonal Antibodies, Combination Drugs, Others.
By Indication: Asthma, COPD (Chronic Obstructive Pulmonary Disease), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Others.
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others.
By Geography: North America (U.S, Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America), and Rest Of The World (Middle East, Africa).

Key Takeaways

• Geographically, North America Pulmonary Drugs Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing predominance of respiratory ailments involving the application of antihistamines in the North American region.
• Pulmonary Drugs Market growth is being driven by the increasing pervasiveness of pulmonary ailments which may involve the application of metered dose inhalers and the expanding population of the elderly. However, the limitations of pulmonary drug delivery like complicated delivery devices being needed to aim medications to the airways and these devices being ineffective are some of the major factors hampering the growth of the Pulmonary Drugs Market. 
• Pulmonary Drugs Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Pulmonary Drugs Market report. 

Pulmonary Drugs Market Segment Analysis – By Drug Class

The Pulmonary Drugs Market based on drug class can be further segmented into Beta-2 Agonists, Anti-Cholinergic Agents, Oral And Inhaled Corticosteroids, Anti-Leukotrienes, Antihistamines, Monoclonal Antibodies, Combination Drugs, and Others. The Combination Drugs Segment held the largest market share in 2021. This growth is owing to the surging sales of combination drugs owing to combination drugs being comparatively safer than other medications. Antihistamines may be utilized as an economical medication in the treatment of certain respiratory ailments. The advent of triple combination drugs is further propelling the growth of the Combination Drugs segment.

Furthermore, the Oral And Inhaled Corticosteroids segment is estimated to grow with the fastest CAGR of 4.5% during the forecast period 2022-2027 owing to the soaring application of inhaled and oral corticosteroids in the treatment of numerous incessant ailments and the benefits of corticosteroids like decreasing inflammation (swelling) and mucus generation in the airways of the lungs apart from the application of antihistamines.

Pulmonary Drugs Market Segment Analysis – By Indication

The Pulmonary Drugs Market based on indication can be further segmented into Asthma, COPD (Chronic Obstructive Pulmonary Disease), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, and Others. The Asthma Segment held the largest market share in 2021. This growth is owing to the increasing predominance of asthma worldwide. Antihistamines obstruct the immune system chemical histamine, which is essential in allergic reactions and may prove advantageous for asthma with an allergic component as per physicians. The proliferating application of drug classes like Bronchodilators (beta-2 agonists, anticholinergics) and Corticosteroids in the treatment of asthma and asthma exacerbations are further propelling the growth of this segment.

Furthermore, the COPD (Chronic Obstructive Pulmonary Disease) segment is estimated to grow with the fastest CAGR of 5.0% during the forecast period 2022-2027 owing to the increasing predominance of COPD (Chronic Obstructive Pulmonary Disease) resulting in the surging application of bronchodilators typically in the form of inhalers for the treatment of COPD (Chronic Obstructive Pulmonary Disease) apart from the application of antihistamines like Spiriva (tiotropium).

Pulmonary Drugs Market Segment Analysis – By Geography

The Pulmonary Drugs Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and Rest of the World. North America (Pulmonary Drugs Market) held the largest share with 38% of the overall market in 2021. The growth of this region is owing to the expanding count of respiratory ailments which may require the application of Antihistamines in the North American region. As per the fact sheets for the state of Ohio maintained by the Centers For Disease Control And Prevention (CDC), among 483 mature grown-ups of Ohio with Chronic Obstructive Pulmonary Disease (COPD), 76.4% recorded that shortness of breath influenced their quality of life. The soaring predominance of smoking and the expanding population of the elderly is further propelling the growth of the Pulmonary Drugs Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the existence of an enormous population base vulnerable to asthma and Chronic Obstructive Pulmonary Disease (COPD) which may require the application of antihistamines in the Asia-Pacific region. The increasing awareness regarding pulmonary ailments and the existence of key players are further fuelling the progress of the Pulmonary Drugs Market in the Asia-Pacific region.

Pulmonary Drugs Market - Drivers

Surging Applications Of Dry Powder Inhalers Are Projected To Drive The Growth Of Pulmonary Drugs Market:

Peak inspiratory flow (PiF, ml/s), is defined as the peak box pressure signal happening at the time of one breath in a negative direction. The peak inspiratory flow rate to distribute powder from most commercially accessible dry powder inhalers (DPIs) is between 30 and 60L/min. These flow rates lead to oropharyngeal doses comparable with that acquired from a pressurized metered-dose inhaler (pMDI) without an add-on device. All DPIs need the patient to prepare the dose prior to inhalation, and the suitable process is detailed in the package insert or patient information leaflet. It is thought-provoking to note that the principal pharmaceutical firms with an interest in inhaled asthma and Chronic Obstructive Pulmonary Disease (COPD) medications appear to be prioritizing the DPI over reformulated HFA pMDIs products. Principally, combination products in DPIs including a long-acting -agonist and a corticosteroid (for example, Advair Diskus and Symbicort Turbuhaler) have been very favorable. The surging applications of dry powder inhalers are therefore fuelling the growth of the Pulmonary Drugs Market during the forecast period 2022-2027.

Soaring Applications Of Pulmonary Medications Are Expected To Boost The Demand For Pulmonary Drugs:

Typical medications utilized in the treatment of pulmonary ailments involve bronchodilators, anti-inflammatory agents, decongestants, antihistamines, antitussives, mucokinetics, respiratory stimulants and depressants, and paralyzing and antimicrobial agents. Disregarding which class a specific medicine belongs to, the reason for its prescription focuses on advancing bronchodilation or alleviating bronchoconstriction, expediting the elimination of secretions from the lungs, enhancing alveolar ventilation, or oxygenation, or optimizing the breathing pattern. Short-acting bronchodilators possess a half-life of 3 to 6 hours, while longer-acting bronchodilators possess a half-life of 18 to 24 hours. The treatment of infection usually includes the administration of antibiotics by a systemic route, like intravenous or oral. However, pulmonary infections can also be accessed by inhalation of antibiotics owing to the infection being more directly accessible through the airways, making inhalation delivery basically topical administration. This technique provides deposition of great antimicrobial concentrations directly at the site of infection, however, with a possibly decreased systemic exposure. There is proof for the application of aerosolized antibiotics for the treatment of numerous conditions like cystic fibrosis (CF), which has evolved into the standard of care for chronic infection, as well as non-CF bronchiectasis, non-tuberculous mycobacteria, and ventilator-associated infection where such therapy does not have a certified indication however has been utilized with expanding frequency. The soaring applications of pulmonary medications are therefore driving the growth of the Pulmonary Drugs Market during the forecast period 2022-2027.

Pulmonary Drugs Market Challenges

Challenges Of Inhalable Medications Are Hampering The Growth Of The Pulmonary Drugs Market:

Inhalable formulations present a challenge. They need to be stable at room temperature, effectively delivered in a reproducible dose, and simple to apply. Formulation problems involve drug absorption, particle size, models for toxicology parameters, and patient compliance. Numerous determinants are influencing the deposition of drug particles in the respiratory tract, like inertia, gravitational sedimentation, and Brownian motion. Lungs possess a huge surface area, making them perfect for drug absorption. They are constituted of two distinct parts, the cartilage-lined tracheobronchial tree and the thin-walled alveolar sacs lined by a dense capillary network, constituting 95% of the whole. However, therapeutics delivered to the lungs to treat lung conditions require to remain inside the lungs instead of being absorbed, owing to their considerable negative impacts on the gut, the heart, the brain, and the blood vessels. Drugs conveyed as aerosols by way of MDIs or DPIs need to have the correct range of particle size. This is owing to this parameter being critical to the deposition of the suitable dose, and the delivery of the drug to the correct location. If the particles are large (>10 m), the aerosol will come to rest on the oropharynx and larynx owing to inertia, while if the size is between 2–5 m, the particles come to rest on the central airways. Tiny particles (0.5–2 m) will arrive at the peripheral airways. If too tiny (below 0.5 m), they flow about without settling and depart the lungs with the ensuing breath. These issues are thus hampering the growth of the Pulmonary Drugs Market.

Pulmonary Drugs Industry Outlook:

Product launches, product approvals, patents and events, acquisitions, partnerships, and collaborations resulting in expansion of business and customer base are key strategies adopted by players in the Pulmonary Drugs Market. Key companies in this market are:

1. AstraZeneca PLC.
2. Boehringer Ingelheim
3. F. Hoffmann-La Roche Ltd.
4. GlaxoSmithKline
5. Grifols S.A.
6. Merck & Co.
7. Pfizer Inc.
8. Regeneron Pharmaceuticals
9. Sumitomo Dainippon Pharma
10. Teva Pharmaceuticals

Acquisitions/Product Launches:

• In December 2021, AstraZeneca has included a novel target for idiopathic pulmonary fibrosis (IPF) in its medication development portfolio, detected utilizing BenevolentAI’s platform. This is notedly the second novel target from the collaboration that has been recognized, approved, and chosen for AstraZeneca’s portfolio. BenevolentAI’s collaboration with AstraZeneca presently targets the detection of possible novel treatments for IPF and chronic kidney disease (CKD).
• In October 2020, AstraZeneca, the British pharmaceutical firm, acquired recommendations by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for authorization of two medications in the European Union (EU). AstraZeneca’s Forxiga and Trixeo Aerosphere, a triple-combination therapy, have been suggested by CHMP for application in the EU. Forxiga is a medication utilized for the treatment of symptomatic chronic heart failure in mature grown-ups with or without type-2 diabetes, while Trixeo Aerosphere is utilized for maintenance treatment in mature grown-up patients with moderate to serious chronic obstructive pulmonary disease (COPD).
• In March 2019, the U.S. Food and Drug Administration (FDA) authorized Orphan Drug Designation (ODD) for saracatinib, a possible novel medication for the treatment of idiopathic pulmonary fibrosis (IPF), a kind of lung ailment that leads to scarring (fibrosis) of the lungs. Saracatinib is an inhibitor of Src kinase which manages broad cell functions involving cell growth and cell differentiation. Saracatinib has finished Phase I development.

Related Reports

Idiopathic Pulmonary Fibrosis Market – Forecast (2022 - 2027)

Report Code: HCR 72933

Pulmonary Edema Market – Forecast (2022 - 2027)

Report Code: HCR 1056

Generic Drugs Market – Forecast (2022 - 2027)

Report Code: HCR 0217 

For more Lifesciences and Healthcare Market reports, please click here